{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:52:55Z","timestamp":1787010775642,"version":"build-2736575974"},"reference-count":24,"publisher":"Cold Spring Harbor Laboratory","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Mol Case Stud"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>\n                    Although\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutations are commonly identified in many solid tumors and the response of\n                    <jats:italic>BRAF<\/jats:italic>\n                    p.V600E-positive tumors to targeted therapy is well documented,\n                    <jats:italic>BRAF<\/jats:italic>\n                    rearrangements are less frequent and are predominantly found in low-grade glioma, melanoma, lung, colorectal, and thyroid carcinoma. Preclinical and clinical studies have demonstrated effectiveness of multiple therapies (RAF-targeted, ERK-targeted, or MEK-targeted) targeting\n                    <jats:italic>BRAF<\/jats:italic>\n                    -fusion harboring tumors. We report a rare\n                    <jats:italic>NRF1-BRAF<\/jats:italic>\n                    fusion with novel breakpoints, identified by next-generation sequencing\u2013based assay, from a 69-year-old man with metastatic urothelial carcinoma (UC) of the renal pelvis and his initial clinical response to a second-generation MEK inhibitor, trametinib, before stopping the medication because of adverse side effects. The\n                    <jats:italic>NRF1-BRAF<\/jats:italic>\n                    fusion has only been reported in a single case of anaplastic pleomorphic xanthoastrocytoma, and\n                    <jats:italic>BRAF<\/jats:italic>\n                    rearrangement has never been reported in UC.\n                  <\/jats:p>","DOI":"10.1101\/mcs.a003848","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T16:55:11Z","timestamp":1555952111000},"page":"a003848","source":"Crossref","is-referenced-by-count":15,"title":["Urothelial carcinoma with an\n                    <i>NRF1-BRAF<\/i>\n                    rearrangement and response to targeted therapy"],"prefix":"10.1101","volume":"5","author":[{"given":"Alexandra L.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya V.","family":"Guseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Bossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2019,4,22]]},"reference":[{"key":"2021112506183215000_5.3.a003848.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2039"},{"key":"2021112506183215000_5.3.a003848.2","unstructured":"Bellmunt J . 2019. Treatment of metastatic urothelial cancer of the bladder and urinary tract. UpToDate. https:\/\/www.uptodate.com\/contents\/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract#H21 ."},{"key":"2021112506183215000_5.3.a003848.3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-398"},{"key":"2021112506183215000_5.3.a003848.4","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12148"},{"key":"2021112506183215000_5.3.a003848.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200523237"},{"key":"2021112506183215000_5.3.a003848.6","doi-asserted-by":"publisher","DOI":"10.1038\/73536"},{"key":"2021112506183215000_5.3.a003848.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.11"},{"key":"2021112506183215000_5.3.a003848.8","doi-asserted-by":"crossref","first-page":"84697","DOI":"10.18632\/oncotarget.20949","article-title":"Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K\/mTOR signaling pathways","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2021112506183215000_5.3.a003848.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0125"},{"key":"2021112506183215000_5.3.a003848.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2097"},{"key":"2021112506183215000_5.3.a003848.11","first-page":"51","article-title":"BRAF alterations in primary brain tumors","volume":"26","year":"2018","journal-title":"Discov Med"},{"key":"2021112506183215000_5.3.a003848.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.05.048"},{"key":"2021112506183215000_5.3.a003848.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67019-X"},{"key":"2021112506183215000_5.3.a003848.14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0245"},{"key":"2021112506183215000_5.3.a003848.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2166"},{"key":"2021112506183215000_5.3.a003848.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1616-3"},{"key":"2021112506183215000_5.3.a003848.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"2021112506183215000_5.3.a003848.18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29825"},{"key":"2021112506183215000_5.3.a003848.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219232110"},{"key":"2021112506183215000_5.3.a003848.20","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.022137"},{"key":"2021112506183215000_5.3.a003848.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.106"},{"key":"2021112506183215000_5.3.a003848.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0274-5"},{"key":"2021112506183215000_5.3.a003848.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature14982"},{"key":"2021112506183215000_5.3.a003848.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3729"}],"container-title":["Molecular Case Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/mcs.a003848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T09:18:41Z","timestamp":1637831921000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecularcasestudies.cshlp.org\/lookup\/doi\/10.1101\/mcs.a003848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,22]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,6,3]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1101\/mcs.a003848"],"URL":"https:\/\/doi.org\/10.1101\/mcs.a003848","relation":{},"ISSN":["2373-2865","2373-2873"],"issn-type":[{"value":"2373-2865","type":"print"},{"value":"2373-2873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,22]]}}}